NCT00336986View on ClinicalTrials.gov

Efficacy Study of IL-21 to Treat Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
CancerMalignant Melanoma
Interventions
DRUG

recombinant interleukin-21

Trial Locations (7)

2145

Novo Nordisk Investigational Site, Westmead

3002

Novo Nordisk Investigational Site, East Melbourne

3050

Novo Nordisk Investigational Site, Parkville

3084

Novo Nordisk Investigational Site, Heidelberg

3128

Novo Nordisk Investigational Site, Box Hill

3144

Novo Nordisk Investigational Site, Malvern

6009

Novo Nordisk Investigational Site, Nedlands

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY